Study Evaluating Renal Cell Carcinoma Risk Factors (MICRA)

Pfizer

Status: Completed

Conditions: Carcinoma, Renal Cell

Treatments: Other: Epidemiological study according to clinical practice

Study type: Observational

Funder types: Industry

Identifiers

NCT00927043

B1771010

3066K1-4433

Details and patient eligibility

About

This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.

Full description

invitation to volunteer

Enrollment: 145 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
• =18 years, any gender.
• Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion criteria

• Patients who have already initiated any kind of specific therapy for the treatment of RCC.2.
• Patients with other neoplasias different from RCC (current or past).

Trial design

145 participants in 1 patient group

1

Treatment:

Other: Epidemiological study according to clinical practice